Pfizer (PFE) Insider Joseph Echevarria Buys $46K of Stock
Joseph Echevarria purchased 1,904 shares of Pfizer Inc. on June 26, 2026, valued at about $46,248.
Reviewed by automated data checks against the source filing. How we make and check alerts
Joseph Echevarria bought 1,904 shares of Pfizer Inc. ($PFE) at an average price of $24.29, worth about $46,248.16, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PFE is down 2.4% after 1 week, up 3.4% after 1 month and up 23.9% to date (from the $23.87 close on Jun 26, 2026).
PFE
Pfizer Inc.
Key Points
- On June 26, 2026, Joseph Echevarria bought 1,904 shares of Pfizer Inc. for approximately $46,248, at a price of $24.29 per share.
- Pfizer's stock is currently priced at $24.37, close to its 52-week low of $23.58, suggesting a potential for growth.
- The company has a market cap of about $158.1 billion and a P/E ratio of 36.5, indicating its valuation in the healthcare sector.
Get $PFE trade alerts by text
We text you when insiders, Congress or big funds trade $PFE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Pfizer Inc. alert may contain errors. Disclosures
Echevarria's Purchase Details
Joseph Echevarria bought 1,904 shares of Pfizer Inc. (NYSE: PFE) on June 26, 2026, for about $46,248. This transaction occurred at a price of $24.29 per share. Echevarria's purchase reflects a personal investment in the pharmaceutical giant, which has been active in the biopharmaceutical market.
Other Insiders Join the Buying
On the same day, several other insiders also bought shares of Pfizer. Shantanu Narayen purchased 2,059 shares at the same price, totaling around $50,013. Cyrus Taraporevala added 1,544 shares, valued at approximately $37,504. James Quincey acquired 1,595 shares, worth about $38,743. This collective buying among executives suggests a shared confidence in the company's future prospects.
How Pfizer Inc. Stock Has Traded
Pfizer's stock is currently trading at $24.37, sitting just above its 52-week low of $23.58. The stock has seen fluctuations, and this recent insider buying may indicate a belief that the shares are undervalued at this price point. The shares have been trading below their 200-day moving average of $26.29, which could signal a potential for recovery in the near future.
Analysts Set New Price Targets
Analysts have maintained a generally neutral outlook on Pfizer. On October 9, 2026, JP Morgan kept its Neutral rating but raised the price target to $30 from $28. Cantor Fitzgerald also maintained a Neutral rating, with a target of $28. Scotiabank rated it as Sector Outperform, with a target of $33. Overall, the consensus suggests cautious optimism among analysts, with a target mean price of $28.87 based on 26 opinions.
What Pfizer Inc. Does
Pfizer Inc. is a leading biopharmaceutical company that develops and sells a wide range of medications and vaccines worldwide. Its diverse portfolio includes treatments for various diseases, including COVID-19, and it has significant market presence in both the United States and internationally. The recent insider purchases might reflect a strong belief in the company's ongoing projects and future growth potential.
What’s Next for Pfizer
Looking ahead, Pfizer is set to release its next earnings report on November 3, 2026. As more insider transactions become public, it will be interesting to see how these activities impact investor sentiment and stock performance. The recent 13F filings and insider trades provide a snapshot of confidence in the company's direction, but market conditions will ultimately dictate the stock's future.
Related Filing Alerts
Source: Joseph Echevarria's Form 4 filing on $PFE (Jun 26, 2026). Find the original filing: PFE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts